Tag Archives: BAYZF

Top Safest Stocks For 2018

QIm 73 years old, and I converted money in a traditional IRA to a Roth IRA in 2016. I know that I have until October 16 to undo the conversion and get back the money I paid in taxes. Will recharacterizing the IRA affect my required minimum distribution for 2017?

SEE ALSO: 6 Tax-Smart Ways to Lower Your RMDs in Retirement
A

Yes. Your required minimum distributions are based on your traditional IRA balance at the end of the previous year. When you convert traditional IRA money to a Roth, that money is removed from future RMD calculations (Roth IRAs are not subject to RMDs for the original owner).

However, if you take advantage of the opportunity to undo the conversion — and retrieve the tax you paid when you reported the converted amount as income — you restore the amount to your traditional IRA, and that increases your RMD. If all or a portion of the conversion is reversed, an adjustment to the December 31, 2016, balance needs to be made, thus increasing the 2017 RMD, says Jeffrey Levine, chief retirement strategist for Ed Slott and Co., an IRA consulting firm.

Top Safest Stocks For 2018: Sohu.com Inc.(SOHU)

Advisors’ Opinion:

  • [By Monica Gerson]

    Sohu.com Inc (NASDAQ: SOHU) is projected to report a quarterly loss at $0.57 per share on revenue of $406.50 million.

    Bank of Hawaii Corporation (NYSE: BOH) is expected to report its quarterly earnings at $0.99 per share on revenue of $149.88 million.

  • [By Belinda Cao]

    Sohu.com Inc. (SOHU), which sold a stake in its search unit to Tencent Holdings Ltd. (700), advanced 11 percent for the week to $72.06. It retreated 5.9 percent Sept. 20. Tencent, Chinas biggest Internet company by market value, paid $448 million for a 36.5 percent stake in Sohus Sogou unit last week and merge its own search service with Sogou.

  • [By Wayne Duggan]

    Sogou is Baidu’s biggest rival when it comes to mobile search engine market share. The app is owned by Sohu.com Inc (NASDAQ: SOHU), and its position as second fiddle to Baidu makes it most similar to Microsoft Corporation (NASDAQ: MSFT)’s Bing.

Top Safest Stocks For 2018: Quidel Corporation(QDEL)

Advisors’ Opinion:

  • [By Lisa Levin]

    Quidel Corporation (NASDAQ: QDEL) shares were also up, gaining 8 percent to $44.31. Piper Jaffray upgraded Quidel from Neutral to Overweight.

    Equities Trading DOWN

Top Safest Stocks For 2018: Snap Interactive, Inc. (STVI)

Advisors’ Opinion:

  • [By Vikram Nagarkar]

    According to recent reports, Snap Inc will now look to go public at a valuation of $19 billion to $22 billion, as it goes public under the ticker symbol SNAP on the New York Stock Exchange. Snap Inc’s move to slash its previous seemingly overambitious target of $25 billion comes across as a very good move. Well, there’s no denying the fact that the upcoming Snapchat IPO has generated a lot of investor interest – to the extent that some “overeager” investors even went ahead and bought shares of a similar sounding company,Snap Interactive (OTC:STVI), sending its shares 140% higher. And Snap Interactive’s relatively paltry $50 million market cap may have something to do with it. Be that as it may, Snapchat’s reported initial valuation target of $25 billion was way too ambitious, and there’s no lack of consensus on that front. However, even the scaled down $19 billion target may not be attractive enough.

Top Safest Stocks For 2018: Grupo Aeroportuario Del Pacifico, S.A. de C.V.(PAC)

Advisors’ Opinion:

  • [By Asit Sharma]

    In its fourth-quarter 2016 earnings filed on Feb. 23, Grupo Aeroportuario del PacificoSAB de CV(NYSE:PAC)capped a year of growth across several important metrics. The Mexican airport operator, which abbreviates its name to GAP, reported increases in revenue, profits, and domestic and international passenger traffic.

Top Safest Stocks For 2018: Bayer Aktiengesellschaft (BAYZF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Online Direct Sales – Once only consumer electronics and mobile handsets, the products it offers has grown to include 15 different categories, including home appliances and a wide array of general merchandise.

    In April, JD.com became a certified member of the American Apparel & Footwear Association (AAFA), the trusted public policy and political voice of the apparel and footwear industry, a first for a Chinese e-commerce company. In the first quarter of 2017, Avene, the leading demo-cosmetic brand for sensitive skin in European pharmacies, and three brands under Georgio Armani launched flagship stores on JD.com’s direct sales platform. JD Worldwide, a cross-border e-commerce platform set up in April 2015 to provide access to international brands (including those not available in China), has retail contracts with international brands such as Wal-Mart (NYSE:WMT), Phillips, Barcelona FC, and GNC (NYSE:GNC). Recently, it’s partnered with ASDA, a leading UK retailer under the Wal-Mart umbrella, as well as Bayer (OTCPK:BAYZF) and Cetaphil. As of March 2017, it operates 263 warehouses covering a gross floor area of 5.8 million square meters. GMV from the online direct sales business was RMB107.9 billion in the first quarter of 2017, up 42% from the first quarter of 2016. Net revenues from online direct sales increased by 40% in the first quarter of 2017 as compared to the first quarter of 2016. Fulfilled orders in the first quarter of 2017 were 477.1 million, an increase of 39% from 342.1 million in the same period in 2016. Fulfilled orders placed through mobile accounted for approximately 81% of total orders fulfilled in the first quarter of 2017, an increase of 56% compared to the same period in 2016.

    Online Marketplace – Third-party sellers offer products to customers and pay a commission to JD.com. They provide transaction processing and billing services on all orders on the online marketplace and leverage their own nationwide fulfillment infrastructu

  • [By SEEKINGALPHA.COM]

    We believe that the pharmaceutical sector has received too much negative attention. Despite the risks, a few companies offer good entry opportunities. In our previous article, we recommended Akorn. Today, we have analyzed Teva. We believe that the company is in a position to thrive in the generic market, and that it is priced very attractively. Yet, we don’t like management’s aggressive M&A strategy. We don’t like very aggressive companies since large acquisitions rarely create value for the shareholders. Contributors argue that Teva has overpaid for Actavis (its latest and largest acquisition) by at least $14B. This does not surprise us since most M&A deals are too expensive. Previous corruption issues add further doubts. Unfortunately, there is no amount of profit that can convince us to invest in a company where we do not like the management. We have sold our positions in Bayer (OTCPK:BAYZF) for similar reasons. We like Bayer, but we have sold our shares because of the Bayer-Monsanto (NYSE:MON) acquisition.

  • [By SEEKINGALPHA.COM]

    And this is pretty important ground. Hepatocellular carcinoma can be managed with local therapy (surgery, embolization, etc.), but at its most advanced stages, the options quickly start to thin out. For a decade, the only option in systemic therapy was Bayer’s (OTCPK:BAYZF) sorafenib. Recently, the effective systemic treatment armamentarium was doubled with the approval of regorafenib for second-line therapy.

  • [By SEEKINGALPHA.COM]

    Other R&D products in Regeneron’s pipeline that we are interested in

    Fasinumab: Antibody against nerve growth factor, being developed for pain treatment like osteoarthritis. It is partnered with Teva Pharmaceutical (NASDAQ:TEVA) (for osteoarthritis, in phase 3), and is also being developed for treatment of chronic back pain. It is licensed to Mitsubishi Tanabe for the Japan territory. REGN2222: For prevention of RSV virus infection in infants, competing with Synagis from AstraZeneca (NYSE:AZN). Nesvacumab: Angiopoetin 2 antibody, being tested in combination with Eylea (in phase 2, partnered with Bayer (OTCPK:BAYZF)). Rinucumab (anti-PDGF): Being tested in treatment of wet AMD in combination with Eylea. Phase 2 trial was not successful, but the treatment duration was less (only 12 weeks versus 24 weeks for rival Ophthotech (NASDAQ:OPHT)). 28-week and 52-week data will be released later. With Ophthotech’s phase 3 failure with Fovista, we are bullish on Rinucumab’s commercial potential in wet AMD. Immuno-oncology pipeline: Checkpoint inhibitors and novel CAR-T; still in early stage.

    Click to enlarge

the best shares

We’re heading into some lighter trading days with the Thanksgiving holiday and the official opening of the Holiday Shopping season. Today’s Three Big Stock Charts looks at a few stocks that have gone parabolic in the month of November and asks “can these stocks go higher?”

Three stocks that are on our “Rocket List” are Best Buy Co Inc (NYSE:BBY), Darden Restaurants, Inc. (NYSE:DRI) and Automatic Data Processing (NASDAQ:ADP), as each of these companies have taken the recent rally to the next level by going parabolic in their ascent.

Best Buy Co Inc (BBY)

the best shares: General Motors Company(GM)

Advisors’ Opinion:

  • [By Paul Ausick]

    General Motors Co. (NYSE: GM) on Friday posted total November U.S. sales of 245,387 vehicles, a decrease of 2.9% compared with November 2016. Retail deliveries dropped 0.1% in the month to 197,340 units, and fleet deliveries rose to 19.6% for the month. Fleet sales now account for 19.4% of 2017 sales.

  • [By Shanthi Rexaline]

    Should General Motors Company (NYSE: GM) split its stock? According to David Einhorn-founded hedge fund Greenlight Capital in a recent presentation, there’s a case for two classes of GM shares to unlock value.

  • [By Michael A. Robinson]

    I recommended Mobileye to you folks on March 31, 2015. I noted that many automakers – Audi AG, Ford Motor Co. (NYSE: F), General Motors Co. (NYSE: GM), Tesla Inc. (Nasdaq: TSLA), and Volvo AB among them – had turned over the keys of their driverless vehicle programs to Mobileye.

  • [By Laurie Kulikowski]

    Even after a recent rally, GM still trades at just 3.1x NTM EBITDAPO, a discount to the low-end of our sense of its normalized historical trading range of roughly 3.5x to 4.5x, despite significant structural improvements in the North American automotive industry and the company, which in our view argue for a premium to history. Auto parts suppliers, for example, trade at material premiums to history (7.0x NTM EBITDAP vs. 5.3x long-run average), largely given the improvements at OEMs such as General Motors, which have made for a structurally healthier and more profitable industry for all market participants. We note GM also sports a 4.0% dividend yield, making it attractive to income oriented investors, and yields 8.5% free cash flow to equity, on our 2016 estimates. GM has another $2.1 billion remaining on a repurchase program management intends to complete by 2016-end, equating to another 4% of shares outstanding (on top of the over 5% repurchased to date). 

the best shares: Sunoco LP(SUN)

Advisors’ Opinion:

  • [By Lisa Levin]

    Friday afternoon, the non-cyclical consumer goods & services sector proved to be a source of strength for the market. Leading the sector was strength from Ballard Power Systems Inc. (USA) (NASDAQ: BLDP) and Sunoco LP (NYSE: SUN).

  • [By Lisa Levin]

    Thursday afternoon, the energy sector proved to be a source of strength for the market. Leading the sector was strength from Ballard Power Systems Inc. (USA) (NASDAQ: BLDP) and Sunoco LP (NYSE: SUN).

  • [By Douglas A. McIntyre]

    Exxon Mobil Corp. (NYSE: XOM) is the second largest company in America and the world’s largest oil company. Chevron Corp. (NYSE: CVX) is the third largest company in the United States. Valero Corp. (NYSE: VLO) is among the world’s largest refiners. Sunoco L.P. (NYSE: SUN) is one of North America’s largest owners of stations and convenience stores. BP PLC (NYSE: BP) is among the world’s oil behemoths. Shell is the U.S. branch of oil giant Royal Dutch Shell PLC (NYSE: RDS-A).

  • [By Lisa Levin]

    Here is the list of stocks going ex-dividend on August 3, 2016.

    J B Hunt Transport Services Inc (NASDAQ: JBHT) – $0.2200 dividend, 1.0791 percent yield
    Johnson Controls Inc (NYSE: JCI) – $0.2900 dividend, 2.6250 percent yield
    FirstEnergy Corp. (NYSE: FE) – $0.3600 dividend, 3.9680 percent yield
    Sunoco LP (NYSE: SUN) – $0.8255 dividend, 10.7347 percent yield
    Wells Fargo & Co (NYSE: WFC) – $0.3800 dividend, 3.1588 percent yield
    BP plc (ADR) (NYSE: BP) – $0.6000 dividend, 6.8768 percent yield
    American Airlines Group Inc (NASDAQ: AAL) – $0.1000 dividend, 1.1442 percent yield
    Heidrick & Struggles International, Inc. (NASDAQ: HSII) – $0.1300 dividend, 2.9834 percent yield
    Alcoa Inc (NYSE: AA) – $0.0300 dividend, 1.1321 percent yield
    Sensient Technologies Corporation (NYSE: SXT) – $0.2700 dividend, 1.5341 percent yield

    Posted-In: Ex-DividendNews Dividends Markets Trading Ideas

the best shares: Preferred Bank(PFBC)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Preferred Bank (PFBC) has surged 54% in the past year but still trades at a modest discount to the median S&P 1500 regional bank, based on both trailing earnings and estimated 2017 profits.

the best shares: Bayer Aktiengesellschaft (BAYZF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Online Direct Sales – Once only consumer electronics and mobile handsets, the products it offers has grown to include 15 different categories, including home appliances and a wide array of general merchandise.

    In April, JD.com became a certified member of the American Apparel & Footwear Association (AAFA), the trusted public policy and political voice of the apparel and footwear industry, a first for a Chinese e-commerce company. In the first quarter of 2017, Avene, the leading demo-cosmetic brand for sensitive skin in European pharmacies, and three brands under Georgio Armani launched flagship stores on JD.com’s direct sales platform. JD Worldwide, a cross-border e-commerce platform set up in April 2015 to provide access to international brands (including those not available in China), has retail contracts with international brands such as Wal-Mart (NYSE:WMT), Phillips, Barcelona FC, and GNC (NYSE:GNC). Recently, it’s partnered with ASDA, a leading UK retailer under the Wal-Mart umbrella, as well as Bayer (OTCPK:BAYZF) and Cetaphil. As of March 2017, it operates 263 warehouses covering a gross floor area of 5.8 million square meters. GMV from the online direct sales business was RMB107.9 billion in the first quarter of 2017, up 42% from the first quarter of 2016. Net revenues from online direct sales increased by 40% in the first quarter of 2017 as compared to the first quarter of 2016. Fulfilled orders in the first quarter of 2017 were 477.1 million, an increase of 39% from 342.1 million in the same period in 2016. Fulfilled orders placed through mobile accounted for approximately 81% of total orders fulfilled in the first quarter of 2017, an increase of 56% compared to the same period in 2016.

    Online Marketplace – Third-party sellers offer products to customers and pay a commission to JD.com. They provide transaction processing and billing services on all orders on the online marketplace and leverage their own nationwide fulfillment infrastructu

  • [By SEEKINGALPHA.COM]

    Other R&D products in Regeneron’s pipeline that we are interested in

    Fasinumab: Antibody against nerve growth factor, being developed for pain treatment like osteoarthritis. It is partnered with Teva Pharmaceutical (NASDAQ:TEVA) (for osteoarthritis, in phase 3), and is also being developed for treatment of chronic back pain. It is licensed to Mitsubishi Tanabe for the Japan territory. REGN2222: For prevention of RSV virus infection in infants, competing with Synagis from AstraZeneca (NYSE:AZN). Nesvacumab: Angiopoetin 2 antibody, being tested in combination with Eylea (in phase 2, partnered with Bayer (OTCPK:BAYZF)). Rinucumab (anti-PDGF): Being tested in treatment of wet AMD in combination with Eylea. Phase 2 trial was not successful, but the treatment duration was less (only 12 weeks versus 24 weeks for rival Ophthotech (NASDAQ:OPHT)). 28-week and 52-week data will be released later. With Ophthotech’s phase 3 failure with Fovista, we are bullish on Rinucumab’s commercial potential in wet AMD. Immuno-oncology pipeline: Checkpoint inhibitors and novel CAR-T; still in early stage.

    Click to enlarge

  • [By SEEKINGALPHA.COM]

    And this is pretty important ground. Hepatocellular carcinoma can be managed with local therapy (surgery, embolization, etc.), but at its most advanced stages, the options quickly start to thin out. For a decade, the only option in systemic therapy was Bayer’s (OTCPK:BAYZF) sorafenib. Recently, the effective systemic treatment armamentarium was doubled with the approval of regorafenib for second-line therapy.

  • [By SEEKINGALPHA.COM]

    We believe that the pharmaceutical sector has received too much negative attention. Despite the risks, a few companies offer good entry opportunities. In our previous article, we recommended Akorn. Today, we have analyzed Teva. We believe that the company is in a position to thrive in the generic market, and that it is priced very attractively. Yet, we don’t like management’s aggressive M&A strategy. We don’t like very aggressive companies since large acquisitions rarely create value for the shareholders. Contributors argue that Teva has overpaid for Actavis (its latest and largest acquisition) by at least $14B. This does not surprise us since most M&A deals are too expensive. Previous corruption issues add further doubts. Unfortunately, there is no amount of profit that can convince us to invest in a company where we do not like the management. We have sold our positions in Bayer (OTCPK:BAYZF) for similar reasons. We like Bayer, but we have sold our shares because of the Bayer-Monsanto (NYSE:MON) acquisition.

invest financial

China’s Huishan Dairy Co. (HKG: 6863) took a note from Sears’ handbook on insider buying – and failed miserably.

Shares of the Chinese stock sank by a record 85% in Hong Kong on Friday in one of the city’s biggest sell-offs, wiping billions from its market value. Before the crash, the firm had a market capitalization of $4.85 billion; now it’s worth only $750 million.

The stock’s collapse is a huge blow to the Red Dragon, as Huishan is the country’s largest dairy farmer and has over 78 farms spread across Greater China. Before Friday’s plunge, Huishan had been one of the most stable stocks in Hong Kong.

The stock stopped trading at HK$0.42, or US$0.05, after which Huishan shares were suspended by Hong Kong’s exchange.

invest financial: Scana Corporation(SCG)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Monday, utilities shares were relative laggards, down on the day by about 0.43 percent. Meanwhile, top losers in the sector included SCANA Corporation (NYSE: SCG), down 2 percent, and FirstEnergy Corp. (NYSE: FE), down 2 percent.

  • [By Lisa Levin]

    In trading on Friday, utilities shares were relative laggards, down on the day by about 0.32 percent. Meanwhile, top losers in the sector included Genie Energy Ltd (NYSE: GNE), down 3 percent, and SCANA Corporation (NYSE: SCG), down 3 percent.

  • [By Lisa Levin]

    In trading on Tuesday, utilities shares rose by just 0.1 percent. Meanwhile, top losers in the sector included Atlantic Power Corp (NYSE: AT), down 2 percent, and SCANA Corporation (NYSE: SCG) down 1 percent.

invest financial: Ebix, Inc.(EBIX)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap insurance software stock Ebix Inc (NASDAQ: EBIX) reported Q1 2017 earnings before the market opened this morning. Q1 revenue rose 11% to $79.1 million and decreased 1% over Q4 2016 revenue of $80.0 million. The year over year revenue improvement reflected growth in the Companys Exchange, Risk Compliance, and Broker Solution channels. On a constant currency basis, Q1 revenue increased 10% to $78.5 millionwith theExchange channel continued to bethe Companyslargest -accounting for 67% of Q1 2017 revenues. Q1 2017 net income rose 19% to $26.4 million with the improvement principally reflected the benefit of higher revenues and operating income as compared to the same period last year.

invest financial: Sotheby's(BID)

Advisors’ Opinion:

  • [By Travis Hoium]

    Shares of auction house Sotheby’s (NYSE:BID) jumped as much as 14.7% in trading Monday after the company released fourth-quarter results. And shares kept steaming, trading 13.6% higher as of 12:30 p.m. EST.

  • [By Marshall Hargrave]

    Now Loeb's looking to put that capital to work in other markets, with the art market being a perfect candidate. Loeb and his Third Point hedge fund have started their latest activist campaign with leading auction house Sotheby's (NYSE: BID). Loeb joins fellow activist investor Marcato Capital in the stock.

  • [By Lisa Levin]

    Sothebys (NYSE: BID) reported better-than-expected results for its fourth quarter on Monday.

    Sothebys posted quarterly adjusted earnings of $1.35 per share on revenue of $308.69 million. Analysts were expecting earnings of $1.17 per share on revenue of $277.28 million.

invest financial: Sapiens International Corporation N.V.(SPNS)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday.
    Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbeat earnings for its first quarter.
    Seres Therapeutics Inc (NASDAQ: MCRB) rose 9.1 percent to $11.39 in pre-market trading after dropping 5.26 percent on Wednesday.
    Plug Power Inc (NASDAQ: PLUG) rose 8.9 percent to $2.45 in pre-market trading after surging 73.08 percent on Wednesday.
    Coach Inc (NYSE: COH) rose 6.7 percent to $41.98 in pre-market trading. Coach named Ian Bickley as President, Global Business Development and Strategic Alliances.
    Sapiens International Corporation N.V. (NASDAQ: SPNS) shares rose 6.1 percent to $13.91 in pre-market trading after gaining 0.54 percent on Wednesday.
    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 6.1 percent to $149.15 in pre-market trading. Jazz Pharma reached a settlement with Hikma Pharma related to Xyrem patent case. Mizuho downgraded Jazz from Buy to Neutral.
    Interactive Brokers Group, Inc. (NASDAQ: IBKR) shares rose 6 percent to $36.72 in pre-market trading after declining 0.03 percent on Wednesday.
    Rewalk Robotics Ltd (NASDAQ: RWLK) rose 5.3 percent to $2.00 in pre-market trading after the company disclosed that the U.S. Department of Veterans Affairs purchased 28 added Exoskeleton Systems.
    Merrimack Pharmaceuticals Inc (NASDAQ: MACK) rose 5.1 percent to $3.29 in pre-market trading. Merrimack declared a $1.06 special dividend.
    BioTime, Inc. (NYSE: BTX) shares rose 4.8 percent to $3.50 in pre-market trading. BioTime, reported the formation of new subsidiary AgeX Therapeutics, Inc.
    Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) shares rose 4.8 percent to $12.26 in pre-market trading after gaining 0.69 percent on Wednesday.
    Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 3.6 percent to $39.15 in pre-market trading after the company posted better-than

invest financial: First Trust NASDAQ-100- Technology Index Fund(QTEC)

Advisors’ Opinion:

  • [By Zacks]

    Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
     
    Amazon.com, Inc. (NASDAQ: AMZN): Free Stock Analysis Report
     
    Netflix, Inc. (NASDAQ: NFLX): Free Stock Analysis Report
     
    Facebook, Inc. (NASDAQ: FB): Free Stock Analysis Report
     
    Alphabet Inc. (NASDAQ: GOOGL): Free Stock Analysis Report
     
    Apple Inc. (NASDAQ: AAPL): Free Stock Analysis Report
     
    SPDR-TECH SELS (ETF:XLK): ETF Research Reports
     
    NASDAQ-100 SHRS (NASDAQ: QQQ): ETF Research Reports
     
    SPDR-SP 500 TR (ETF:SPY): ETF Research Reports
     
    PWRSH-DYN SEMI (ETF:PSI): ETF Research Reports
     
    ISHARS-NA TEC-S (ETF:IGV): ETF Research Reports
     
    FIRST N-100 TEC (NASDAQ: QTEC): ETF Research Reports
     
    FT-TECH ALPHA (ETF:FXL): ETF Research Reports
     
    FT-NDQ SEMICON (FTXL): ETF Research Reports
     
    NVIDIA Corporation (NASDAQ: NVDA): Free Stock Analysis Report
     
    Macy's Inc (NYSE: M): Free Stock Analysis Report
     
    To read this article on Zacks.com click here.
     
    Zacks Investment Research
     
    Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

invest financial: Bayer Aktiengesellschaft (BAYZF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    We believe that the pharmaceutical sector has received too much negative attention. Despite the risks, a few companies offer good entry opportunities. In our previous article, we recommended Akorn. Today, we have analyzed Teva. We believe that the company is in a position to thrive in the generic market, and that it is priced very attractively. Yet, we don’t like management’s aggressive M&A strategy. We don’t like very aggressive companies since large acquisitions rarely create value for the shareholders. Contributors argue that Teva has overpaid for Actavis (its latest and largest acquisition) by at least $14B. This does not surprise us since most M&A deals are too expensive. Previous corruption issues add further doubts. Unfortunately, there is no amount of profit that can convince us to invest in a company where we do not like the management. We have sold our positions in Bayer (OTCPK:BAYZF) for similar reasons. We like Bayer, but we have sold our shares because of the Bayer-Monsanto (NYSE:MON) acquisition.

  • [By SEEKINGALPHA.COM]

    Other R&D products in Regeneron’s pipeline that we are interested in

    Fasinumab: Antibody against nerve growth factor, being developed for pain treatment like osteoarthritis. It is partnered with Teva Pharmaceutical (NASDAQ:TEVA) (for osteoarthritis, in phase 3), and is also being developed for treatment of chronic back pain. It is licensed to Mitsubishi Tanabe for the Japan territory. REGN2222: For prevention of RSV virus infection in infants, competing with Synagis from AstraZeneca (NYSE:AZN). Nesvacumab: Angiopoetin 2 antibody, being tested in combination with Eylea (in phase 2, partnered with Bayer (OTCPK:BAYZF)). Rinucumab (anti-PDGF): Being tested in treatment of wet AMD in combination with Eylea. Phase 2 trial was not successful, but the treatment duration was less (only 12 weeks versus 24 weeks for rival Ophthotech (NASDAQ:OPHT)). 28-week and 52-week data will be released later. With Ophthotech’s phase 3 failure with Fovista, we are bullish on Rinucumab’s commercial potential in wet AMD. Immuno-oncology pipeline: Checkpoint inhibitors and novel CAR-T; still in early stage.

    Click to enlarge

  • [By SEEKINGALPHA.COM]

    And this is pretty important ground. Hepatocellular carcinoma can be managed with local therapy (surgery, embolization, etc.), but at its most advanced stages, the options quickly start to thin out. For a decade, the only option in systemic therapy was Bayer’s (OTCPK:BAYZF) sorafenib. Recently, the effective systemic treatment armamentarium was doubled with the approval of regorafenib for second-line therapy.

stock market results for today

Apple is getting into the smart speaker market with the HomePod, the company’s first entirely new product in three years. It’s a relatively young hardware category made popular by the Amazon Echo.

Now, more tech companies are rushing out their own versions of the device. You’ve probably heard about talking speakers, but perhaps you’ve wondered how they work and what they mean for your privacy.

Here’s everything you need to know about tech’s hottest new gadgets.

What is a smart speaker?

A smart speaker is a small Wi-Fi connected speaker controlled with voice commands. To use the hands-free device, you speak a trigger phrase “Hey Siri,” “OK Google,” “Alexa” and then ask a question such as “what’s the weather?” or make a request like “order a Lyft.” The speakers are powered by smart assistants like Siri and Alexa that talk back.

What is it used for?

A smart speaker is primarily used to stream music and news, set timers and reminders, manage shopping lists, and control connected-home devices like lights or thermostats. Amazon recently added message and call options, so the speakers will likely be used even more for communication in the future. The Echo is handy for ordering things from Amazon Prime, but it struggles with answering basic knowledge questions. Meanwhile, the Google Home, unsurprisingly, is great for Googling things.

stock market results for today: Gartner, Inc.(IT)

Advisors’ Opinion:

  • [By Lisa Levin]

    CEB Inc. (NYSE: CEB) shares were also up, gaining 21 percent to $74.90 after Gartner Inc (NYSE: IT) announced plans to acquire the company for $2.6 billion in cash and stock.

stock market results for today: Unifirst Corporation(UNF)

Advisors’ Opinion:

  • [By Monica Gerson]

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

    AeroVironment, Inc. (NASDAQ: AVAV) posted upbeat earnings for its fourth quarter, but the company missed analysts’ sales expectations. AeroVironment shares dipped 7.37 percent to $26.40 in the after-hours trading session.
    Analysts are expecting Acuity Brands, Inc. (NYSE: AYI) to have earned $2.03 per share on revenue of $847.79 million in the latest quarter. Acuity Brands shares rose 0.04 percent to $244.75 in after-hours trading.
    CalAmp Corp. (NASDAQ: CAMP) reported stronger-than-expected results for its first quarter and reported a $25 million buyback plan. The company also issued a weak sales forecast for the current quarter. CalAmp shares gained 0.35 percent to $14.14 in the after-hours trading session.
    UniFirst Corp (NYSE: UNF) is expected to report its quarterly earnings at $1.34 per share on revenue of $366.28 million. UniFirst shares slipped 0.72 percent to close at $105.44 on Tuesday.
    A Schulman Inc (NASDAQ: SHLM) reported better-than-expected earnings for its third quarter. A Schulman shares rose 1.61 percent to $21.51 in the after-hours trading session.

    Posted-In: Stocks To WatchEarnings News Guidance Pre-Market Outlook Markets Trading Ideas

  • [By Monica Gerson]

     

    General Mills, Inc. (NYSE: GIS) is expected to report its quarterly earnings at $0.60 per share on revenue of $3.86 billion.
    Pier 1 Imports Inc (NYSE: PIR) is projected to post a quarterly loss at $0.05 per share on revenue of $420.05 million.
    Acuity Brands, Inc. (NYSE: AYI) is estimated to report its quarterly earnings at $2.03 per share on revenue of $847.79 million.
    Monsanto Company (NYSE: MON) is projected to report its quarterly earnings at $2.40 per share on revenue of $4.49 billion.
    Worthington Industries, Inc. (NYSE: WOR) is expected to report its quarterly earnings at $0.64 per share on revenue of $692.48 million.
    Progress Software Corporation (NASDAQ: PRGS) is projected to post its quarterly earnings at $0.29 per share on revenue of $94.64 million.
    UniFirst Corp (NYSE: UNF) is estimated to report its quarterly earnings at $1.34 per share on revenue of $366.28 million.
    Exfo Inc (NASDAQ: EXFO) is expected to post its quarterly earnings at $0.06 per share on revenue of $60.87 million.
    OMNOVA Solutions Inc. (NYSE: OMN) is projected to report its quarterly earnings at $0.14 per share on revenue of $205.40 million.
    8Point3 Energy Partners LP (NASDAQ: CAFD) is estimated to post a quarterly loss at $0.01 per share on revenue of $11.60 million.
    Park Electrochemical Corp. (NYSE: PKE) is expected to report its quarterly earnings at $0.22 per share on revenue of $35.30 million.
    Xplore Technologies Corp. (NASDAQ: XPLR) is projected to post its quarterly earnings at $0.01 per share on revenue of $24.00 million.
    Investors Real Estate Trust (NYSE: IRET) is expected to post its quarterly earnings at $0.14 per share on revenue of $56.87 million.
    Tel-Instrument Electronics Corp. (NYSE: TIK) is estimated to post earnings for the latest quarter.
    Aethlon Medical, Inc. (NASDAQ: AEMD) is expected to post a quarterly loss at $0.20 per share.
    Ossen Innovation Co Ltd (ADR) (NASDAQ: OSN) is projected to post ea

  • [By Monica Gerson]

    UniFirst Corp (NYSE: UNF) is estimated to report its quarterly earnings at $1.26 per share on revenue of $362.62 million.

    Progress Software Corporation (NASDAQ: PRGS) is projected to post its quarterly earnings at $0.29 per share on revenue of $93.15 million.

stock market results for today: Rovi Corporation(ROVI)

Advisors’ Opinion:

  • [By Emily Stewart]

    Rovi (ROVI) is a new second-quarter acquisition for Soros, who as of the end of the period owns 4.1 million shares worth $63.6 million.

    Rovi is engaged in the discovery, delivery, display and monetization of digital entertainment by providing a broad set of integrated solutions. It has a $1.8 billion market cap. 

stock market results for today: Federated Investors, Inc.(FII)

Advisors’ Opinion:

  • [By Gregg Greenberg]

     Stocks of Federated Investors (FII) fell approximately 9% in 2015, yet Oja expects a big turnaround in 2016, once again due to the prospect of higher rates ahead. 

     

    "The money market fund business, which is unprofitable now, should become more profitable as rates rise because Federated has to reimburse for the servicing fees for these funds," said Oja, who also admires the fund company’s 3.5% dividend yield. 

     

    Oja added that Federated also has a "good core business of equity and fixed-income asset management." 

stock market results for today: Greenhill & Co., Inc.(GHL)

Advisors’ Opinion:

  • [By Jim Robertson]

    For investors with a long memory, the Iridium communications service was launched on November 1, 1998 only for the founding company to go into Chapter 11 bankruptcy nine months later as the cost of service was prohibitive for many users. Iridium Satellite LLC was eventually merged with a special purpose acquisition company (GHQ) created by the investment bank Greenhill & Co. (NYSE: GHL) in September 2009 to form Iridium Communications.

  • [By Lisa Levin]

    In trading on Friday, financial shares slipped by 0.55 percent. Meanwhile, top losers in the sector included Greenhill & Co., Inc. (NYSE: GHL), down 11 percent, and SVB Financial Group (NASDAQ: SIVB), down 8 percent.

stock market results for today: Bayer Aktiengesellschaft (BAYZF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Other R&D products in Regeneron’s pipeline that we are interested in

    Fasinumab: Antibody against nerve growth factor, being developed for pain treatment like osteoarthritis. It is partnered with Teva Pharmaceutical (NASDAQ:TEVA) (for osteoarthritis, in phase 3), and is also being developed for treatment of chronic back pain. It is licensed to Mitsubishi Tanabe for the Japan territory. REGN2222: For prevention of RSV virus infection in infants, competing with Synagis from AstraZeneca (NYSE:AZN). Nesvacumab: Angiopoetin 2 antibody, being tested in combination with Eylea (in phase 2, partnered with Bayer (OTCPK:BAYZF)). Rinucumab (anti-PDGF): Being tested in treatment of wet AMD in combination with Eylea. Phase 2 trial was not successful, but the treatment duration was less (only 12 weeks versus 24 weeks for rival Ophthotech (NASDAQ:OPHT)). 28-week and 52-week data will be released later. With Ophthotech’s phase 3 failure with Fovista, we are bullish on Rinucumab’s commercial potential in wet AMD. Immuno-oncology pipeline: Checkpoint inhibitors and novel CAR-T; still in early stage.

    Click to enlarge

  • [By SEEKINGALPHA.COM]

    Online Direct Sales – Once only consumer electronics and mobile handsets, the products it offers has grown to include 15 different categories, including home appliances and a wide array of general merchandise.

    In April, JD.com became a certified member of the American Apparel & Footwear Association (AAFA), the trusted public policy and political voice of the apparel and footwear industry, a first for a Chinese e-commerce company. In the first quarter of 2017, Avene, the leading demo-cosmetic brand for sensitive skin in European pharmacies, and three brands under Georgio Armani launched flagship stores on JD.com’s direct sales platform. JD Worldwide, a cross-border e-commerce platform set up in April 2015 to provide access to international brands (including those not available in China), has retail contracts with international brands such as Wal-Mart (NYSE:WMT), Phillips, Barcelona FC, and GNC (NYSE:GNC). Recently, it’s partnered with ASDA, a leading UK retailer under the Wal-Mart umbrella, as well as Bayer (OTCPK:BAYZF) and Cetaphil. As of March 2017, it operates 263 warehouses covering a gross floor area of 5.8 million square meters. GMV from the online direct sales business was RMB107.9 billion in the first quarter of 2017, up 42% from the first quarter of 2016. Net revenues from online direct sales increased by 40% in the first quarter of 2017 as compared to the first quarter of 2016. Fulfilled orders in the first quarter of 2017 were 477.1 million, an increase of 39% from 342.1 million in the same period in 2016. Fulfilled orders placed through mobile accounted for approximately 81% of total orders fulfilled in the first quarter of 2017, an increase of 56% compared to the same period in 2016.

    Online Marketplace – Third-party sellers offer products to customers and pay a commission to JD.com. They provide transaction processing and billing services on all orders on the online marketplace and leverage their own nationwide fulfillment infrastructu

  • [By SEEKINGALPHA.COM]

    We believe that the pharmaceutical sector has received too much negative attention. Despite the risks, a few companies offer good entry opportunities. In our previous article, we recommended Akorn. Today, we have analyzed Teva. We believe that the company is in a position to thrive in the generic market, and that it is priced very attractively. Yet, we don’t like management’s aggressive M&A strategy. We don’t like very aggressive companies since large acquisitions rarely create value for the shareholders. Contributors argue that Teva has overpaid for Actavis (its latest and largest acquisition) by at least $14B. This does not surprise us since most M&A deals are too expensive. Previous corruption issues add further doubts. Unfortunately, there is no amount of profit that can convince us to invest in a company where we do not like the management. We have sold our positions in Bayer (OTCPK:BAYZF) for similar reasons. We like Bayer, but we have sold our shares because of the Bayer-Monsanto (NYSE:MON) acquisition.

  • [By SEEKINGALPHA.COM]

    And this is pretty important ground. Hepatocellular carcinoma can be managed with local therapy (surgery, embolization, etc.), but at its most advanced stages, the options quickly start to thin out. For a decade, the only option in systemic therapy was Bayer’s (OTCPK:BAYZF) sorafenib. Recently, the effective systemic treatment armamentarium was doubled with the approval of regorafenib for second-line therapy.

stock market technical analysis

The U.S. Air Force dispatched a nuclear sniffer plane today to the Sea of Japan, which is east of the Korean Peninsula.

“The WC-135 Constant Phoenix, a special-purpose U.S. plane, made an emergency sortie today over the East Sea,” an anonymous source told the Korean news outlet Yonhap this morning.

WC-135 Constant Phoenix sniffer plane, Oct. 10, 2006.

WC-135 Constant Phoenix sniffer plane, Oct. 10, 2006.Today’s flight “appears meant to check whether the secretive Communist nation [of North Korea] has detonated a nuclear bomb,” Yonhap explained.

stock market technical analysis: Bayer Aktiengesellschaft (BAYZF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Other R&D products in Regeneron’s pipeline that we are interested in

    Fasinumab: Antibody against nerve growth factor, being developed for pain treatment like osteoarthritis. It is partnered with Teva Pharmaceutical (NASDAQ:TEVA) (for osteoarthritis, in phase 3), and is also being developed for treatment of chronic back pain. It is licensed to Mitsubishi Tanabe for the Japan territory. REGN2222: For prevention of RSV virus infection in infants, competing with Synagis from AstraZeneca (NYSE:AZN). Nesvacumab: Angiopoetin 2 antibody, being tested in combination with Eylea (in phase 2, partnered with Bayer (OTCPK:BAYZF)). Rinucumab (anti-PDGF): Being tested in treatment of wet AMD in combination with Eylea. Phase 2 trial was not successful, but the treatment duration was less (only 12 weeks versus 24 weeks for rival Ophthotech (NASDAQ:OPHT)). 28-week and 52-week data will be released later. With Ophthotech’s phase 3 failure with Fovista, we are bullish on Rinucumab’s commercial potential in wet AMD. Immuno-oncology pipeline: Checkpoint inhibitors and novel CAR-T; still in early stage.

    Click to enlarge

  • [By SEEKINGALPHA.COM]

    And this is pretty important ground. Hepatocellular carcinoma can be managed with local therapy (surgery, embolization, etc.), but at its most advanced stages, the options quickly start to thin out. For a decade, the only option in systemic therapy was Bayer’s (OTCPK:BAYZF) sorafenib. Recently, the effective systemic treatment armamentarium was doubled with the approval of regorafenib for second-line therapy.

  • [By SEEKINGALPHA.COM]

    We believe that the pharmaceutical sector has received too much negative attention. Despite the risks, a few companies offer good entry opportunities. In our previous article, we recommended Akorn. Today, we have analyzed Teva. We believe that the company is in a position to thrive in the generic market, and that it is priced very attractively. Yet, we don’t like management’s aggressive M&A strategy. We don’t like very aggressive companies since large acquisitions rarely create value for the shareholders. Contributors argue that Teva has overpaid for Actavis (its latest and largest acquisition) by at least $14B. This does not surprise us since most M&A deals are too expensive. Previous corruption issues add further doubts. Unfortunately, there is no amount of profit that can convince us to invest in a company where we do not like the management. We have sold our positions in Bayer (OTCPK:BAYZF) for similar reasons. We like Bayer, but we have sold our shares because of the Bayer-Monsanto (NYSE:MON) acquisition.

  • [By SEEKINGALPHA.COM]

    Online Direct Sales – Once only consumer electronics and mobile handsets, the products it offers has grown to include 15 different categories, including home appliances and a wide array of general merchandise.

    In April, JD.com became a certified member of the American Apparel & Footwear Association (AAFA), the trusted public policy and political voice of the apparel and footwear industry, a first for a Chinese e-commerce company. In the first quarter of 2017, Avene, the leading demo-cosmetic brand for sensitive skin in European pharmacies, and three brands under Georgio Armani launched flagship stores on JD.com’s direct sales platform. JD Worldwide, a cross-border e-commerce platform set up in April 2015 to provide access to international brands (including those not available in China), has retail contracts with international brands such as Wal-Mart (NYSE:WMT), Phillips, Barcelona FC, and GNC (NYSE:GNC). Recently, it’s partnered with ASDA, a leading UK retailer under the Wal-Mart umbrella, as well as Bayer (OTCPK:BAYZF) and Cetaphil. As of March 2017, it operates 263 warehouses covering a gross floor area of 5.8 million square meters. GMV from the online direct sales business was RMB107.9 billion in the first quarter of 2017, up 42% from the first quarter of 2016. Net revenues from online direct sales increased by 40% in the first quarter of 2017 as compared to the first quarter of 2016. Fulfilled orders in the first quarter of 2017 were 477.1 million, an increase of 39% from 342.1 million in the same period in 2016. Fulfilled orders placed through mobile accounted for approximately 81% of total orders fulfilled in the first quarter of 2017, an increase of 56% compared to the same period in 2016.

    Online Marketplace – Third-party sellers offer products to customers and pay a commission to JD.com. They provide transaction processing and billing services on all orders on the online marketplace and leverage their own nationwide fulfillment infrastructu

stock market technical analysis: Ligand Pharmaceuticals Incorporated(LGND)

Advisors’ Opinion:

  • [By Keith Speights]

    Research and development is the lifeblood of biotech companies. The potential for new drugs also serves as a primary factor driving biotech stocks higher and higher. That’s been the case for Celgene (NASDAQ:CELG), Ionis Pharmaceuticals (NASDAQ:IONS), and Ligand Pharmaceuticals (NASDAQ:LGND).

  • [By Keith Speights, Sean Williams, and Cory Renauer]

    So when we asked three of our top healthcare contributors to name three of the best stocks to invest in healthcare, it’s not surprising that their responses listed companies in three different industries: medical device makerMasimo (NASDAQ:MASI), pharmacy services giant CVS Health (NYSE:CVS) and biopharmaceutical company Ligand Pharmaceuticals (NASDAQ:LGND). Here’s why these three healthcare stocks stand out as smart picks.

stock market technical analysis: Occidental Petroleum Corporation(OXY)

Advisors’ Opinion:

  • [By Michael Flannelly]

    Early on Monday, analysts at Deutsche Bank lowered their price target on Occidental Petroleum Corporation (OXY) to reflect a lower-than-expected valuation of an asset that the oil and gas exploration company is trying to sell.

    Though the analysts lowered OXY’s price target from $114 to $109, they still maintain a “Buy” rating on the stock. The new price target suggests a 22% upside to the stock’s Friday closing price of $89.49.

    Deutsche Bank analyst Paul Sankey said, “Bloomberg Finance LP reports that Oxy is seeking sale of 40% of Mideast operations for around $8bn, which would imply $20bn total value for the unit. However reportedly some suitors are valuing the asset at around $15bn. This is a relatively negative valuation against our previous view that Oxy would be seeking $25+bn for its MENA business. We are cutting our price target to $109/share to reflect this lower implied valuation.”

    Occidental Petroleum shares were up 96 cents, or 1.07%, during pre-market trading on Monday. The stock is up 16.81% year-to-date.

  • [By Ben Levisohn]

    We have seen several dividend cuts in the recent past, including Anadarko Petroleum cutting its dividend by 81%…and we expect more companies to follow suit. Chesapeake Energy (CHK), ConocoPhillips (COP), Encana,Marathon Oil and Noble Energy (NBL) are among energy companies that have also cut dividends in the past 12 months, but dividend requirements even after several cuts will consume ~26% of 2016 estimated cash flow at current dividend rates (15% excluding Occidental Petroleum (OXY)) for the large cap E&Ps we cover. We believe most of the companies with a dividend yield of more than 1.5% should consider cutting the dividend and find the following companies more likely than not to reduce dividends:Apache (2.5% yield),Devon Energy (4%),Encana (1.5%) andMarathon Oil (2.5%). We believe Canadian Natural Resource (CNQ) (3.0%) is likely to maintain its dividend while Occidental (4.5%) has the financial strength to maintain or even increase the dividend…

  • [By Lee Jackson]

    These companies also reported insider buying last week: Carrizo Oil and Gas Inc. (NASDAQ: CRZO), Medifast Inc. (NYSE: MED), Medley Capital Corp. (NYSE: MCC), Occidental Petroleum Corp. (NYSE: OXY) and Sothebys (NYSE: BID).

  • [By Garrett Cook]

    Citi notes that presentations from producers (the bank specifically notes Anadarko (NYSE: APC), Occidental Petroleum (NYSE: OXY), and Pioneer Natural Resources (NYSE: PXD)) showed a lack of commitment to enter 2017 hedge programs to lock in the economics for drilling.

  • [By Paul Ausick]

    Occidental Petroleum Corp. (NYSE: OXY) dropped about 1.6% Friday, to post a new 52-week low of $64.19 after closing at $65.25 on Thursday. The stock’s 52-week high is $78.48. Volume was about 15% below the daily average of around 4.7 million shares. The company had no specific news.

  • [By Ben Levisohn]

    Stocks that made the cut include General Motors (GM), Coca-Cola Company (KO), Occidental Petroleum (OXY), JPMorgan Chase (JPM), and General Electric (GE).

stock market technical analysis: Fiat Chrysler Automobiles N.V.(FCAU)

Advisors’ Opinion:

  • [By Douglas A. McIntyre]

    After several blows to its quality reputation from major research firms like Consumer Reports and J.D. Power, Fiat Chrysler Automobiles N.V. (NYSE: FCAU) has been let down by its dealers. In the new J.D. Power 2017 U.S. Customer Service Index (CSI) Study, the manufacturer’s Fiat, Jeep, Ram and Dodge took the bottom four spots. The company’s Chrysler brand ranked almost as poorly.

  • [By Douglas A. McIntyre]

    Image a car company with sales off 19% through the first 11 months of the year. Imagine a car company that routinely ranks at or near the bottom of the evaluations of Consumer Reports, J.D. Power rankings and the American Customer Satisfaction Index. Imagine a car company that routinely has 100 days of vehicle in inventory, compared to an industry average near70. That company isFiat, the small car division of Fiat Chrysler Automobiles N.V. (NYSE: FCAU).

  • [By John Rosevear]

    The fifth-generation version of Honda’s well-regarded kid-hauler doesn’t look a whole lot different from the outgoing model, but it packs a slew of upgradesand some useful technology that Honda hopes will make it more competitive with fierce rivals from Toyota (NYSE:TM) and Fiat Chrysler Automobiles (NYSE:FCAU).

  • [By Jeremy Bowman]

    As for individual stocks, Fiat Chrysler(NYSE:FCAU) shares dove 10.3% after the EPA accused the automaker of cheating on emissions tests, similar to the way Volkswagendid. Elsewhere,Hess(NYSE:HES) shares dropped 4.8% after the oil company revealed $4.6 billion in charges for Q4 2016.